Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-TROP-2 antibody-drug conjugate DB-1305

An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) covalently linked, via a cleavable linker containing maleimide tetrapeptide, to the topoisomerase-1 inhibitor P1021, with potential antineoplastic activity. Upon administration of the anti-TROP-2 ADC DB-1305, the anti-TROP-2 antibody targets and binds to TROP-2 expressed on tumor cells. Upon binding and internalization, the topoisomerase-1 inhibitor P1021 is released, and inhibits DNA topoisomerase-1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of TROP-2-expressing tumor cells. TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC DB-1305
anti-TROP-2 ADC DB-1305
anti-TROP-2/P1021 ADC DB-1305
anti-TROP-2/topoisomerase-1 inhibitor ADC DB-1305
DITAC DB-1305
Code name:DB 1305
DB-1305
DB1305
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search